TY - JOUR
T1 - Differential immunotoxicities of poly(ethylene glycol)- vs. poly(carboxybetaine)-coated nanoparticles
AU - Elsabahy, Mahmoud
AU - Li, Ang
AU - Zhang, Fuwu
AU - Sultan, Deborah
AU - Liu, Yongjian
AU - Wooley, Karen L.
N1 - Funding Information:
We gratefully acknowledge financial support from the National Heart Lung and Blood Institute of the National Institutes of Health as a Program of Excellence in Nanotechnology ( HHSN268201000046C ), and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health ( R01-DK082546 ). The Welch Foundation is gratefully acknowledged for support through the W. T. Doherty–Welch Chair in Chemistry , Grant No. A-0001 .
PY - 2013
Y1 - 2013
N2 - Although the careful selection of shell-forming polymers for the construction of nanoparticles is an obvious parameter to consider for shielding of core materials and their payloads, providing for prolonged circulation in vivo by limiting uptake by the immune organs, and thus, allowing accumulation at the target sites, the immunotoxicities that such shielding layers elicit is often overlooked. For instance, we have previously performed rigorous in vitro and in vivo comparisons between two sets of nanoparticles coated with either non-ionic poly(ethylene glycol) (PEG) or zwitterionic poly(carboxybetaine) (PCB), but only now report the immunotoxicity and anti-biofouling properties of both polymers, as homopolymers or nanoparticle-decorating shell, in comparison to the uncoated nanoparticles, and Cremophor-EL, a well-known low molecular weight surfactant used for formulation of several drugs. It was found that both PEG and PCB polymers could induce the expression of cytokines in vitro and in vivo, with PCB being more immunotoxic than PEG, which corroborates the in vivo pharmacokinetics and biodistribution profiles of the two sets of nanoparticles. This is the first study to report on the ability of PEG, the most commonly utilized polymer to coat nanomaterials, and PCB, an emerging zwitterionic anti-biofouling polymer, to induce the secretion of cytokines and be of potential immunotoxicity. Furthermore, we report here on the possible use of immunotoxicity assays to partially predict in vivo pharmacokinetics and biodistribution of nanomaterials.
AB - Although the careful selection of shell-forming polymers for the construction of nanoparticles is an obvious parameter to consider for shielding of core materials and their payloads, providing for prolonged circulation in vivo by limiting uptake by the immune organs, and thus, allowing accumulation at the target sites, the immunotoxicities that such shielding layers elicit is often overlooked. For instance, we have previously performed rigorous in vitro and in vivo comparisons between two sets of nanoparticles coated with either non-ionic poly(ethylene glycol) (PEG) or zwitterionic poly(carboxybetaine) (PCB), but only now report the immunotoxicity and anti-biofouling properties of both polymers, as homopolymers or nanoparticle-decorating shell, in comparison to the uncoated nanoparticles, and Cremophor-EL, a well-known low molecular weight surfactant used for formulation of several drugs. It was found that both PEG and PCB polymers could induce the expression of cytokines in vitro and in vivo, with PCB being more immunotoxic than PEG, which corroborates the in vivo pharmacokinetics and biodistribution profiles of the two sets of nanoparticles. This is the first study to report on the ability of PEG, the most commonly utilized polymer to coat nanomaterials, and PCB, an emerging zwitterionic anti-biofouling polymer, to induce the secretion of cytokines and be of potential immunotoxicity. Furthermore, we report here on the possible use of immunotoxicity assays to partially predict in vivo pharmacokinetics and biodistribution of nanomaterials.
KW - Cremophor-EL
KW - Immunotoxicity
KW - Nanoparticles
KW - Poly(carboxybetaine)
KW - Poly(ethylene glycol)
KW - Protein adsorption
UR - http://www.scopus.com/inward/record.url?scp=84884399980&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2013.09.010
DO - 10.1016/j.jconrel.2013.09.010
M3 - Article
C2 - 24056145
AN - SCOPUS:84884399980
SN - 0168-3659
VL - 172
SP - 641
EP - 652
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 3
ER -